Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RILONACEPT vs RISDIPLAM: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RILONACEPT vs RISDIPLAM: Safety Overview

Metric RILONACEPT RISDIPLAM
Total FAERS Reports 843 3,619
Deaths Reported 14 336
Death Rate 1.7% 9.3%
Hospitalizations 65 719
Average Patient Age 51.9 yrs 21.8 yrs
% Female Patients 68.2% 55.2%
FDA Approval Date N/A Aug 7, 2020
Manufacturer Kiniksa Pharmaceuticals (UK), Ltd. Genentech, Inc.
Route SUBCUTANEOUS ORAL
Marketing Status Prescription Prescription